Virtual Screening: An Alternative or Complement to High Throughput Screening?: Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999
In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene vari...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Dordrecht
Springer Netherlands
2002
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication |
| Beschreibung: | 1 Online-Ressource (XI, 295 p. 53 illus., 18 illus. in color) |
| ISBN: | 9780306468834 |
| DOI: | 10.1007/0-306-46883-2 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046146837 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2002 |||| o||u| ||||||eng d | ||
| 020 | |a 9780306468834 |9 978-0-306-46883-4 | ||
| 024 | 7 | |a 10.1007/0-306-46883-2 |2 doi | |
| 035 | |a (ZDB-2-SME)978-0-306-46883-4 | ||
| 035 | |a (OCoLC)1119104254 | ||
| 035 | |a (DE-599)BVBBV046146837 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 615.1 |2 23 | |
| 245 | 1 | 0 | |a Virtual Screening: An Alternative or Complement to High Throughput Screening? |b Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 |c edited by Gerhard Klebe |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 2002 | |
| 300 | |a 1 Online-Ressource (XI, 295 p. 53 illus., 18 illus. in color) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication | ||
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Computer Applications in Chemistry | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Chemistry | |
| 700 | 1 | |a Klebe, Gerhard |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789048155842 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792366331 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401740784 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/0-306-46883-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031527022 | ||
| 966 | e | |u https://doi.org/10.1007/0-306-46883-2 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180485332533248 |
|---|---|
| any_adam_object | |
| author2 | Klebe, Gerhard |
| author2_role | edt |
| author2_variant | g k gk |
| author_facet | Klebe, Gerhard |
| building | Verbundindex |
| bvnumber | BV046146837 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-0-306-46883-4 (OCoLC)1119104254 (DE-599)BVBBV046146837 |
| dewey-full | 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 |
| dewey-search | 615.1 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/0-306-46883-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03707nmm a2200433zc 4500</leader><controlfield tag="001">BV046146837</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2002 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780306468834</subfield><subfield code="9">978-0-306-46883-4</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/0-306-46883-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-0-306-46883-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119104254</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146837</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Virtual Screening: An Alternative or Complement to High Throughput Screening?</subfield><subfield code="b">Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999</subfield><subfield code="c">edited by Gerhard Klebe</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 295 p. 53 illus., 18 illus. in color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Computer Applications in Chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemistry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klebe, Gerhard</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789048155842</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792366331</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401740784</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/0-306-46883-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031527022</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/0-306-46883-2</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046146837 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9780306468834 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031527022 |
| oclc_num | 1119104254 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XI, 295 p. 53 illus., 18 illus. in color) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Springer Netherlands |
| record_format | marc |
| spelling | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 edited by Gerhard Klebe Dordrecht Springer Netherlands 2002 1 Online-Ressource (XI, 295 p. 53 illus., 18 illus. in color) txt rdacontent c rdamedia cr rdacarrier In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication Pharmacy Computer Applications in Chemistry Chemistry Klebe, Gerhard edt Erscheint auch als Druck-Ausgabe 9789048155842 Erscheint auch als Druck-Ausgabe 9780792366331 Erscheint auch als Druck-Ausgabe 9789401740784 https://doi.org/10.1007/0-306-46883-2 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 Pharmacy Computer Applications in Chemistry Chemistry |
| title | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 |
| title_auth | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 |
| title_exact_search | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 |
| title_full | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 edited by Gerhard Klebe |
| title_fullStr | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 edited by Gerhard Klebe |
| title_full_unstemmed | Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 edited by Gerhard Klebe |
| title_short | Virtual Screening: An Alternative or Complement to High Throughput Screening? |
| title_sort | virtual screening an alternative or complement to high throughput screening proceedings of the workshop new approaches in drug design and discovery special topic virtual screening schloβ rauischholzhausen germany march 15 18 1999 |
| title_sub | Proceedings of the Workshop ‘New Approaches in Drug Design and Discovery’, special topic ‘Virtual Screening’, Schloβ Rauischholzhausen, Germany, March 15–18, 1999 |
| topic | Pharmacy Computer Applications in Chemistry Chemistry |
| topic_facet | Pharmacy Computer Applications in Chemistry Chemistry |
| url | https://doi.org/10.1007/0-306-46883-2 |
| work_keys_str_mv | AT klebegerhard virtualscreeninganalternativeorcomplementtohighthroughputscreeningproceedingsoftheworkshopnewapproachesindrugdesignanddiscoveryspecialtopicvirtualscreeningschlobrauischholzhausengermanymarch15181999 |